Results of a Phase 2b Trial With GB001, a Prostaglandin D2 Receptor 2 Antagonist, in Moderate to Severe Eosinophilic Asthma
Mark H. Moss, Njira Lugogo, Mario Castro, Nicola A. Hanania, Andrea Ludwig-Sengpiel, Dinesh Saralaya, Rafał Dobek, Íñigo Ojanguren, Ivan Vyshnyvetskyy, Jean‐Marie Bruey, Robin Osterhout, Cindy‐ann Tompkins, Karen Dittrich, Kartik Raghupathi, Héctor Ortega
Topics & Concepts
MedicinePlaceboAsthmaInternal medicineDiscontinuationGastroenterologyPopulationExhaled nitric oxideEosinophilProstaglandin D2Adverse effectClinical endpointRandomized controlled trialProstaglandinPathologySpirometryAlternative medicineEnvironmental healthAsthma and respiratory diseasesDelphi Technique in ResearchEosinophilic Disorders and Syndromes